TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Nov. 6, 2026, MedPage Today roundup highlighted three developments: warnings about a small breast cancer risk associated with certain menopause hormone therapies, ASCO’s estimate of a roughly 2% Medicare payment cut for oncologists in 2027, and evidence that routine breast imaging may not benefit some women after double mastectomy for ductal carcinoma in situ. The brief reports do not provide the underlying study details, policy calculations or clinical guidance needed to assess each issue fully.
A Nov. 6 cancer-news roundup reported warnings that certain menopause hormone therapies carry a small increase in breast cancer risk, while the American Society of Clinical Oncology said oncologists treating Medicare patients face a roughly 2% payment cut in 2027. The report also cited UCLA Health on findings that routine mammograms or other breast imaging may not benefit some women treated for ductal carcinoma in situ with a double mastectomy.
The hormone-therapy item, attributed by the roundup to The New York Times, said doctors were warning against overlooking a small increase in breast cancer risk associated with certain hormonal treatments for menopause symptoms. The brief did not identify the specific therapies, quantify the added risk, or provide details about how duration of use or patient characteristics affect it. A separate Guardian report noted that the U.S. Food and Drug Administration had removed boxed warnings about breast cancer, cardiovascular disease and dementia from the labels of three estrogen patches. The two items describe different developments; the roundup does not explain how the FDA’s label decision relates to the risk warning.
ASCO said oncologists treating Medicare patients will face an approximately 2% reduction under the 2027 Physician Fee Schedule from the Centers for Medicare & Medicaid Services. The roundup did not give the calculation, specify which oncology services or practices would be most affected, or report a response from CMS. ASCO also said it was monitoring possible effects on cancer care after monsoon flooding closed a facility in India that manufactures sterile injectable generic oncology medicines. No details were given about the facility’s output, the length of the closure or any resulting supply disruption.
On post-mastectomy imaging, the roundup cited UCLA Health for the finding that women who had a double mastectomy to treat ductal carcinoma in situ (DCIS) may not benefit from routine mammograms or other breast imaging. The brief did not identify the study design, patient numbers or whether the finding applies to particular risk groups. It does not establish that every patient can stop imaging or follow-up; decisions about surveillance depend on clinical circumstances and guidance from a treating team.
Effects on Patients and Cancer Care
The three items touch different decisions but could affect the same patients and clinicians: how to weigh treatment for menopause symptoms, how oncology practices plan for Medicare reimbursement, and how to follow patients after surgery for DCIS. The hormone-therapy report underscores that a risk described as small still warrants discussion, while the FDA label change may prompt questions about how warnings are communicated. Neither item, as summarized here, supplies enough information to determine an individual patient’s risk or treatment choice.
A projected 2% Medicare payment cut could put pressure on oncology practices, although the roundup does not quantify likely effects on staffing, services or access. The reported flooding-related factory closure adds a separate supply concern: sterile injectable medicines are used in cancer treatment, but no shortage or interruption was confirmed in the source material. For patients who have had a double mastectomy, the imaging finding may inform conversations about surveillance, but should not be treated as a universal instruction to discontinue follow-up.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Therabody ThermBack LED 4-in-1 Heated Lower Back Relief Wrap
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
As an affiliate, we earn on qualifying purchases.
Three Developments in One Roundup
The source is a short MedPage Today cancer-news roundup dated November 6, 2026, rather than a single study or policy announcement. It gathers reports from other outlets and organizations across oncology. The hormone-treatment warning was attributed to The New York Times, the FDA label development to The Guardian, and the post-mastectomy imaging item to UCLA Health. ASCO supplied the statement about Medicare reimbursement and said it was monitoring the effect of flooding on a drug-manufacturing facility.
These distinctions matter because the roundup provides brief summaries, not the underlying evidence or documents. The FDA label change concerns three named only by drug class as estrogen patches in the supplied material; the source does not list product names or explain the agency’s reasoning. The payment item concerns the 2027 CMS fee schedule, while the imaging finding is specific in the brief to women treated for DCIS with a double mastectomy. The items should not be read as one coordinated policy change or as a single clinical recommendation.
“Oncologists treating Medicare patients will face a roughly 2% pay cut under the 2027 Physician Fee Schedule from CMS.”
— American Society of Clinical Oncology (ASCO), as reported by MedPage Today
Evidence and Policy Details Pending
The roundup does not include the underlying studies or full reports for the hormone-risk and post-mastectomy imaging items. The size and circumstances of the reported hormone-related risk, including which treatments it covers, remain unspecified. It is also unclear which patients were included in the imaging analysis and whether it supports different surveillance for particular groups.
For the payment issue, the source does not show how ASCO calculated the roughly 2% figure, whether the estimate reflects a final CMS policy or how payment changes might vary by service. It also does not say how long the Indian manufacturing facility will remain closed, which medicines it makes, or whether the closure has affected supply. The FDA item lacks the names of the three patches and details on the label decision. These gaps mean the brief supports reporting the developments, but not stronger conclusions about clinical effects or service availability.
Watch CMS, FDA and Clinical Guidance
The next relevant milestones are further detail on the 2027 CMS Physician Fee Schedule and any response from CMS or oncology groups about its likely effects. ASCO’s stated monitoring of the India facility will be more informative if it is followed by an update on the closure, production and medicine supply. The supplied source does not give a timetable for either development.
Patients weighing menopause hormone therapy or follow-up after mastectomy should discuss their circumstances with a clinician rather than treating this short roundup as personal medical guidance. Further reporting or the underlying research would be needed to clarify which hormone regimens and post-surgical patients the findings concern. The source also does not indicate whether the FDA will issue additional information about the revised estrogen-patch labels.
Key Questions
Does the report say all menopause hormone therapy increases breast cancer risk?
No. It refers to a small increase associated with certain hormonal therapies, but does not name them or give enough detail to apply the warning to all treatments.
What is the reported Medicare pay cut for oncologists?
ASCO said oncologists treating Medicare patients face a roughly 2% cut under the 2027 Physician Fee Schedule. The roundup does not provide the calculation or explain the effects on individual practices.
Can patients stop mammograms after a double mastectomy for DCIS?
The source says routine imaging may not benefit some women in this group, but it does not establish a universal rule. Patients should discuss their own follow-up plan with their care team.
Has the flooding caused a shortage of cancer medicines?
The roundup reports that flooding closed a facility in India that makes sterile injectable generic oncology medicines. It does not confirm a shortage or report how long the closure will last.
Source: medpagetoday.com
